Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 2/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL567630 | 1.00 | HDAC6 (0.35) | HDAC6HDAC1HDAC2CA14MAPK1 | |
| SCHEMBL27854161 | 1.00 | HDAC6 (0.35) | HDAC6HDAC1HDAC2CA14MAPK1 | |
| SCHEMBL21877076 | 0.91 | CA14 (0.39) | HDAC6HDAC1HDAC2CA14MAPK1 | |
| SCHEMBL566482 | 0.85 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA14NOS1 | |
| SCHEMBL27854137 | 0.85 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA14NOS1 | |
| SCHEMBL567227 | 0.85 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA14NOS1 | |
| SCHEMBL566483 | 0.85 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA14NOS1 | |
| SCHEMBL567228 | 0.85 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA14NOS1 | |
| SCHEMBL19891780 | 0.84 | DPP4 (0.37) | HDAC6HDAC1HDAC2CA14CA1 | |
| SCHEMBL566188 | 0.83 | CA14 (0.40) | HDAC6HDAC1HDAC2CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102448941-B | The isoquinilone derivatives replaced | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2016-04-06 | — | — | CN | disclosed |
| EP-2444395-B1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | WESTERN THERAPEUTICS INST INC D (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-8951997-B2 | Substituted isoquinoline derivative | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2015-02-10 | — | — | US | disclosed |
| CN-102448941-A | Substituted isoquinoline derivatives | WESTERN THERAPEUTICS INST INC D | 2012-05-09 | — | — | CN | disclosed |
| EP-2444395-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. Western Therapeutics Institute, Inc. (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035159-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVE | SULT1A1, SULT1E1, SULT2A1 | HDAC6 1027/4885HDAC1 1159/4885HDAC2 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.